Status:
UNKNOWN
Evaluation of Novel Diagnostic Tests for COVID-19
Lead Sponsor:
CCTU- Cancer Theme
Conditions:
Acute Disease
Coronavirus
Eligibility:
All Genders
16+ years
Brief Summary
COVID-19 (also known as Coronavirus) originated in the Wuhan China and has since spread to at least 159 countries around the world. It was declared a pandemic by the World health organisation on the 1...
Eligibility Criteria
Inclusion
- 16 years or above
- Patient requiring hospital admission AND AT LEAST ONE OF
- Clinical or Radiological evidence of pneumonia
- Acute respiratory distress syndrome
- Influenza like illness (defined as fever \>37.8oC and at least one of the following respiratory symptoms, which much be of acute onset: persistent cough (with or without sputum), hoarseness, nasal discharge or congestion, shortness of breath, sore throat, wheezing, sneezing)
Exclusion
- Patients who have not had the standard PHE COVID-19 test applied
- Unwilling or unable to comply with research swab of nose \& throat or tracheal fluid
Key Trial Info
Start Date :
April 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 7 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04326387
Start Date
April 6 2020
End Date
October 7 2021
Last Update
May 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ